TAAR1 agonists for nicotine addiction

TAAR1 激动剂治疗尼古丁成瘾

基本信息

  • 批准号:
    10092996
  • 负责人:
  • 金额:
    $ 39.44万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-04-01 至 2024-02-28
  • 项目状态:
    已结题

项目摘要

ABSTRACT Tobacco smoking remains a major public health concern globally. Although there are FDA-approved therapeutic options available, they are far from adequate to maintain long-term smoking abstinence in most smokers. Thus, discovering novel efficacious pharmacotherapies to aid in smoking cessation remains an urgent clinical need. Nicotine, the major component in tobacco that is responsible for tobacco addiction, stimulates the mesolimbic dopaminergic system via activating nicotinic acetylcholine receptors (nAChRs). Nicotine replacement therapy and the nAChR partial agonist varenicline have achieved limited clinical success by directly modulating the central nAChRs. Indirect modulation of dopaminergic system by non-dopaminergic mechanism may also be able to modulate the addiction-related effects of nicotine. Trace amine associated receptor 1 (TAAR1) has emerged as a novel target for the development of potential pharmacotherapy to treat drug addiction. In particular, our preliminary data have shown that acute TAAR1 agonist treatment is able to reduce some addiction-related effects of nicotine. The objective of the present application is to systematically assess the therapeutic potential of TAAR1 agonists on nicotine addiction. Three Specific Aims are proposed: Aim 1 will examine the effects of repeated TAAR1 agonists (full agonist RO5166017 and partial agonist RO5263397) treatment on nicotine reinforcement using a short-access (1 hour) nicotine self-administration paradigm; Aim 2 will examine the effects of TAAR1 agonists on the reinstatement and incubation of nicotine- seeking behavior in rats with a long-access (21 hours) nicotine self-administration history; Aim 3 will examine the effects of TAAR1 agonists on nicotine withdrawal in rats with a long-access (21 hours) nicotine self- administration history. Collectively, the proposed studies systematically evaluate the effects of TAAR1 agonists on four critical aspects of nicotine addiction (e.g., reinforcing effects, reinstatement, incubation and withdrawal symptoms), each of which is thought to contribute significantly to nicotine dependence and relapse. Successful execution of the proposed studies will confirm the essential role TAAR1 in mediating nicotine addiction and provide critical preclinical evidence in support of developing TAAR1 agonists are novel pharmacotherapy for smoking cessation.
摘要 吸烟仍然是全球主要的公共卫生问题。虽然有FDA批准的 尽管有治疗选择,但它们远远不足以维持大多数人的长期戒烟。 吸烟者。因此,发现新的有效的药物疗法来帮助戒烟仍然是一个挑战。 临床急需。尼古丁是烟草中导致烟草成瘾的主要成分, 通过激活烟碱乙酰胆碱受体(nAChR)刺激中脑边缘多巴胺能系统。 尼古丁替代疗法和nAChR部分激动剂伐伦克林取得了有限的临床成功 通过直接调节中枢nAChRs非多巴胺能神经元对多巴胺能系统的间接调节 这种机制也可能能够调节尼古丁的成瘾相关作用。痕量胺相关 受体1(TAAR 1)已成为开发潜在药物治疗的新靶点, 毒瘾特别是,我们的初步数据表明,急性TAAR 1激动剂治疗能够 减少尼古丁的一些成瘾作用。本申请的目的是系统地 评估TAAR 1激动剂对尼古丁成瘾的治疗潜力。提出了三个具体目标: 目的1将检查重复的TAAR 1激动剂(完全激动剂R 0 5166017和部分激动剂R 0 5166017)的作用。 RO 5263397)使用短时间(1小时)尼古丁自我给药对尼古丁强化的治疗 范例;目标2将检查TAAR 1激动剂对尼古丁的恢复和孵育的影响- 具有长期(21小时)尼古丁自我给药史的大鼠的寻找行为;目标3将检查 TAAR 1激动剂对长期(21小时)尼古丁自我摄取大鼠尼古丁戒断的影响, 行政史。总的来说,拟议的研究系统地评价了TAAR 1激动剂的作用, 尼古丁成瘾的四个关键方面(例如,强化效应、恢复、潜伏和消退 症状),其中每一个被认为是显着贡献尼古丁依赖和复发。成功 执行拟议的研究将证实TAAR 1在介导尼古丁成瘾中的重要作用, 提供关键的临床前证据,支持开发TAAR 1激动剂, 戒烟。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jun-Xu Li其他文献

Jun-Xu Li的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jun-Xu Li', 18)}}的其他基金

Development of LPA5 Antagonists as Analgesics
LPA5 拮抗剂镇痛药的开发
  • 批准号:
    10638278
  • 财政年份:
    2023
  • 资助金额:
    $ 39.44万
  • 项目类别:
TAAR1 agonists for nicotine addiction
TAAR1 激动剂治疗尼古丁成瘾
  • 批准号:
    10561715
  • 财政年份:
    2019
  • 资助金额:
    $ 39.44万
  • 项目类别:
TAAR1 agonists for nicotine addiction
TAAR1 激动剂治疗尼古丁成瘾
  • 批准号:
    9892992
  • 财政年份:
    2019
  • 资助金额:
    $ 39.44万
  • 项目类别:
TAAR1 agonists for nicotine addiction
TAAR1 激动剂治疗尼古丁成瘾
  • 批准号:
    10353373
  • 财政年份:
    2019
  • 资助金额:
    $ 39.44万
  • 项目类别:
TAAR 1 modulation of addiction-related effects of nicotine
TAAR 1 调节尼古丁成瘾相关效应
  • 批准号:
    9182100
  • 财政年份:
    2016
  • 资助金额:
    $ 39.44万
  • 项目类别:
TAAR 1 modulation of addiction-related effects of nicotine
TAAR 1 调节尼古丁成瘾相关效应
  • 批准号:
    9307798
  • 财政年份:
    2016
  • 资助金额:
    $ 39.44万
  • 项目类别:
Imidazoline I2 receptors as targets for the treatment of pain
咪唑啉 I2 受体作为治疗疼痛的靶点
  • 批准号:
    9186516
  • 财政年份:
    2013
  • 资助金额:
    $ 39.44万
  • 项目类别:
IMIDAZOLINE I2 RECEPTORS AS TARGETS FOR THE TREATMENT OF PAIN
咪唑啉 I2 受体作为治疗疼痛的靶点
  • 批准号:
    9170057
  • 财政年份:
    2013
  • 资助金额:
    $ 39.44万
  • 项目类别:
Imidazoline I2 receptors as targets for the treatment of pain
咪唑啉 I2 受体作为治疗疼痛的靶标
  • 批准号:
    8970695
  • 财政年份:
    2013
  • 资助金额:
    $ 39.44万
  • 项目类别:
Behavioral effects of methamphetamine & imidazoline I2 receptor ligands
甲基苯丙胺对行为的影响
  • 批准号:
    8581533
  • 财政年份:
    2013
  • 资助金额:
    $ 39.44万
  • 项目类别:

相似海外基金

Elucidation of acute poisoning mechanism due to abuse of CB1 receptor agonist.
阐明滥用 CB1 受体激动剂引起的急性中毒机制。
  • 批准号:
    21K17323
  • 财政年份:
    2021
  • 资助金额:
    $ 39.44万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of acute poisoning mechanism due to abuse of CB1 receptor agonist.
阐明滥用 CB1 受体激动剂引起的急性中毒机制。
  • 批准号:
    19K19485
  • 财政年份:
    2019
  • 资助金额:
    $ 39.44万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Tissue repair effect in acute myocardial infarction through mobilization of endogenous Muse cells by sphingosine-1-phosphate receptor 2 agonist
1-磷酸鞘氨醇受体2激动剂动员内源性Muse细胞对急性心肌梗死的组织修复作用
  • 批准号:
    18K15843
  • 财政年份:
    2018
  • 资助金额:
    $ 39.44万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
EFFECT OF ACUTE E PROSTAGLANDIN AGONIST N BAL EICO
急性 E 型前列腺素激动剂 N BAL EICO 的作用
  • 批准号:
    6115624
  • 财政年份:
    1998
  • 资助金额:
    $ 39.44万
  • 项目类别:
EFFECT OF ACUTE E PROSTAGLANDIN AGONIST N BAL EICO
急性 E 型前列腺素激动剂 N BAL EICO 的作用
  • 批准号:
    6219539
  • 财政年份:
    1998
  • 资助金额:
    $ 39.44万
  • 项目类别:
EFFECT OF ACUTE E PROSTAGLANDIN AGONIST N BAL EICO
急性 E 型前列腺素激动剂 N BAL EICO 的作用
  • 批准号:
    6276858
  • 财政年份:
    1997
  • 资助金额:
    $ 39.44万
  • 项目类别:
ACUTE CHRONIC HORMONAL CHANGES WITH LHRH-AGONIST THERAPY
LHRH 激动剂治疗引起的急性慢性荷尔蒙变化
  • 批准号:
    6250152
  • 财政年份:
    1997
  • 资助金额:
    $ 39.44万
  • 项目类别:
ACUTE CHRONIC HORMONAL CHANGES WITH LHRH-AGONIST THERAPY
LHRH 激动剂治疗引起的急性慢性荷尔蒙变化
  • 批准号:
    6279945
  • 财政年份:
    1997
  • 资助金额:
    $ 39.44万
  • 项目类别:
EFFECT OF ACUTE E PROSTAGLANDIN AGONIST N BAL EICO
急性 E 型前列腺素激动剂 N BAL EICO 的作用
  • 批准号:
    6246787
  • 财政年份:
    1997
  • 资助金额:
    $ 39.44万
  • 项目类别:
PSYCHOPHARMACOLOGY OF DA AGONIST CNS EFFECTS: ACUTE AND CHRONIC STUDIES
DA 激动剂中枢神经系统影响的精神药理学:急性和慢性研究
  • 批准号:
    3891471
  • 财政年份:
  • 资助金额:
    $ 39.44万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了